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Antibody-mediated neutralizationThe envelope (E) protein is composed of three domains (ED1, ED2 and ED3) with ED3 targeted by the most
potent neutralizing antibodies. DENV-2 strains can be divided into six genotypes. Comparison of ED3 of
representative strains of the six genotypes revealed that there are nine variable residues that are speciﬁc
to a given genotype. Recombinant ED3s (rED3s) of six different DENV-2 strains representing all nine variable
residues were expressed, and their reactivity against a panel of two DENV-2 type-speciﬁc and three DENV
complex-reactive monoclonal antibodies (mAbs) were compared. The differences in binding afﬁnity to the
rED3s representing different DENV-2 genotypes were relatively small, with the exception of type-speciﬁc-
mAb 3H5 that showed up to 10-fold differences in binding between genotypes. Overall the binding differ-
ences did not lead to detectable differences in neutralization. Based on these results, DENV-2 ED3-speciﬁc
neutralizing antibodies will likely be effective against DENV-2 strains from all six genotypes.
© 2011 Elsevier Inc. All rights reserved.Introduction
The disease dengue (DEN) is caused by four mosquito-borne,
genetically and serologically related viruses, termed dengue virus 1
(DENV-1), DENV-2, DENV-3, and DENV-4. The DENVs are members
of the genus Flavivirus, family Flaviviridae. There are approximately
100 million DENV infections annually, with 2.1 million cases of severe
disease manifestations, including dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) (Kyle and Harris, 2008). The geo-
graphic range of the DENVs encompasses most of the tropical and
sub-tropical regions of the world, putting approximately 3 billion
people at risk for infection and this places a large burden on public
health infrastructure (Kyle and Harris, 2008). DENVs are maintained
in nature by two transmission cycles, the sylvatic cycle (occurring
between forest dwelling mosquitoes and non-human primates) and
the urban cycle (occurring between the primary vectors Aedes aegypti
and Aedes albopictus and humans). Studies by Sabin have shown that
human volunteers previously infected with DENV-1 or DENV-2 had
short term herterotypic immunity to infection by both viruses,, University of Texas Medical
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tional Institute for Allergy and
rive Bethesda, MD 20892-8009,
rights reserved.followed by long-term homotypic immunity to the original infecting
DENV (Sabin, 1952).
Even though the four DENVs cause very similar disease manifesta-
tions, they are quite genetically diverse, having about 40% amino acid
sequence divergence. EachDENV can be further subdivided into speciﬁc
genotypes, which can have up to 6% genetic divergence (Twiddy
et al., 2002). Speciﬁcally, six DENV-2 genotypes have been identiﬁed:
American, American/Asian, Asian I, Asian II, cosmopolitan, and sylvatic
(Twiddy et al., 2002). There is evidence to suggest that the DENV geno-
types have different phenotypes and disease outcomes, which has
become an area of great interest (Leitmeyer et al., 1999; Rico-Hesse et
al., 1997). Limited studies suggest that the Asian genotypes are epide-
miologically associated with greater disease outcomes (i.e. DHF/DSS),
whereas the American genotype has been considered less virulent,
since it is associated primarily with the less severe dengue fever
(Rico-Hesse et al., 1997; Watts et al., 1999).
The DEN virion is enveloped, 50 nM in diameter, and contains a
single-stranded, positive-sense RNA genome that is approximately
11 kb in length (Chambers et al., 1990). The genome encodes one
open reading frame that is translated into a single polyprotein that is
co-and post-translationally processed by host and viral proteases to
yield three structural proteins (capsid (C), pre-membrane/ membrane
(prM/M), and envelope (E)) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Rice et al., 1985). Ninety
anti-parallel E protein homodimers are arranged on the surface of
the viral envelope in a herringbone fashion that lacks traditional T=3
symmetry (Kuhn et al., 2002). The molecular arrangement of the E
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ments at the two-, three-, and ﬁve-fold axes of symmetry that have
been shown to be important for antibody binding (Kaufmann et al.,
2006; Kuhn et al., 2002; Lok et al., 2008; Nybakken et al., 2005).
The E protein plays multiple roles in the virus life cycle, which
include receptor binding, entry and fusion with the endosomal mem-
brane. The E protein is composed of three ectodomains designated
domain 1 (ED1), ED2 and ED3. ED1 is the central domain connecting
ED2 and ED3, ED2 is the dimerization domain and also contains the
highly conserved fusion loop (Allison et al., 2001; Rey et al., 1995),
and ED3 is thought to be the receptor-binding domain. Evidence in
support of ED3 as the receptor binding domain include the fact that
ED3 protrudes farthest from the viral surface and soluble forms of
ED3 block infection (by potentially competing for the receptor), as
well as ED3-speciﬁc antibodies can neutralize virus infectivity (Chin
et al., 2007; Crill and Roehrig, 2001; Hung et al., 2004; Kuhn et al.,
2002; Rey et al., 1995). At least twelve major antigenic sites have
been identiﬁed on the DENV-2 E protein (Gromowski and Barrett,
2007; Gromowski et al., 2008; Roehrig et al., 1998; Sukupolvi-Petty
et al., 2007). There are two overlapping antigenic sites located on
the surface of ED3; one is a DENV-2 type-speciﬁc antigenic site and
the other is a DENV complex-reactive antigenic site (Gromowski
and Barrett, 2007; Gromowski et al., 2008; Roehrig et al., 1998;
Sukupolvi-Petty et al., 2007). Evidence suggests that the majority of
antibodies produced during infection target epitopes in proximity to
the fusion loop at the distal end of ED2 (Crill and Roehrig, 2001;
Throsby et al., 2006), however, those that bind ED3 are the most po-
tent at neutralizing virus ((Roehrig et al., 1998). The mechanism(s)
by which ﬂaviviruses are neutralized by antibody are not well under-
stood, but it is thought that neutralization occurs by potentially
blocking receptor binding, preventing endocytosis, inhibiting fusion
with the endosome, or a combination of these mechanisms (Pierson
et al., 2008).
The objective of the current study was to determine if amino acid
sequence variation within ED3 among different DENV-2 genotypesFig. 1. ED3 of different DENV-2 genotypes. Panel A: Alignment representing the ED3 inform
with the type-speciﬁc and complex-reactive critical residues highlighted light gray, and thehas an effect on the afﬁnity and neutralization efﬁcacy of DENV-2
type-speciﬁc and DENV complex-reactive ED3-speciﬁc mAbs.
Results
Amino acid variation among the DENV-2 genotypes
DENV-2 amino acid diversity was determined by aligning the E
protein sequences from 84 representative strains (downloaded from
Genbank). Variable residues among genotypes were deﬁned as amino
acid substitutions that occurred in at least half of the representative
strains composing a particular genotype. The alignment revealed that
there are 31 variable residues in the E protein, nine ofwhichwere locat-
ed in ED3: V308I, I322V, G330D, R345K, V365I, I378V, I379V, and
N390D or N390S (Fig. 1A). Six of these variable residues are surface
exposed (V308I, G330D, R345K, H346Y, I379V, and N390D/S); and
three variable residues have conservative substitutions (V308I, R345K,
and I379V) (Fig. 1B). The remaining three residues are non-
conservative substitutions includingG330D (found in the sylvatic geno-
type only), H346Y, (identiﬁed in half of the Asian I genotype isolates),
and the N390S (cosmopolitan genotype) or N390D (American geno-
type). These variable residues were not critical for the binding of the
DENV-2 type-speciﬁc or DENV complex-reactive antibodies in previous
studies (Gromowski and Barrett, 2007; Gromowski et al., 2008;
Sukupolvi-Petty et al., 2007).
Six DENV-2 strains from four different genotypes (Asian II, cosmo-
politan, sylvatic and American) were chosen to evaluate if variable
residues between genotypes and/or virus strain speciﬁc variation,
within ED3, affected antibody binding afﬁnity and virus neutraliza-
tion (virus passage history is shown in Table 1). We did not investi-
gate Asian I or Asian/American genotype viruses because most of
these viruses had either identical ED3 sequences or contained conser-
vative substitutions in ED3 and were represented by strains already
being used. The DENV-2 Asian II genotype virus strain, New Guinea
C (NGC), served as a reference as it has been used in our previousative sites, the residues that are bolded are surface exposed. Panel B: Structure of ED3
surface exposed informative sites highlighted in dark gray.
Table 1
DENV-2 Passage history.
Straina Host Year isolated Country of origin Passage historyb
New Guinea C Human 1944 New Guinea SM p26, C6/36 p17
H8-2027 Mosquito 1969 Indonesia Vero p1, C6/36 p3
DaKHD10674 Human 1970 Senegal Vero p1, C6/36 p10
DaKaRA578 Mosquito 1980 Ivory Coast SM p8, C6/36 p7
PR159 Human 1969 Puerto Rico PGMK p6, C6/36 p7
SML6420 Human 1994 United States of
America, Texas
C6/36 p11
a DENV-2 strains were obtained from the University of Texas Medical Branch World
Reference Center of for Emerging Virus and Arboviruses.
b SM = suckling mouse; C6/36 = Aedes albopictus cell line; Vero = African green
monkey kidney cell line; PGMK = primary green monkey kidney cells; pX = times
passaged.
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Strain H8-2027 was chosen as the representative of the cosmopolitan
genotype. Two sylvatic genotype virus strains (DakHD10674 and
DakAr578) were chosen because they contain the most variable resi-
dues among DENV-2 genotypes. Finally, two American genotype virus
strains (PR159 and SML6420) were chosen. The speciﬁc amino acid
sequences from these strains are shown in Fig. 2.
Effect of amino acid substitutions on physical binding by mAbs
The DENV-2 type-speciﬁc and DENV complex-reactive antigenic
sites have been shown to each consist of overlapping epitopes
(Gromowski and Barrett, 2007; Gromowski et al., 2008), therefore, a
panel of ﬁve mAbs (two DENV-2 type-speciﬁc and three DENV
complex-reactive antibodies) was used to evaluate if the variable res-
idues within ED3 among DENV-2 genotypes affected mAb afﬁnity.
The epitopes and neutralization properties of three of these mAbs
(3H5, GTX29202 and 20-783-74014) were previously characterized
using the DENV-2 Asian genotype II strain NGC (Gromowski and
Barrett, 2007).
The amino acid variation among the six viruses tested in this study
had the largest effects on the binding of the DENV-2 type-speciﬁc
mAb 3H5, followed by mAb ICL2 (Table 2). The largest difference in
the afﬁnities of mAb 3H5 for rED3 were between DakHD10674 (KD=
0.5±0.04nM), H8-2027 (KD=3.2±0.3nM) and SML6420 (KD=4.9±
0.5nM), including a 10-fold difference between DakHD10674 and
SML6420. The differences among these viruseswere shown to be statis-
tically signiﬁcant by one-way ANOVA (Pb0.05). For mAb ICL2, the larg-
est difference in afﬁnity was between DakHD10674 (0.7±0.1nM) and
PR159 (2.4±0.3nM), a 3.4 fold difference, which was statistically sig-
niﬁcant (Pb0.05). The binding of the two DENV-2 type-speciﬁc mAbs
(3H5, and ICL2) to rED3 from the six DENV-2 representatives followed
a particular pattern; the KD of the two mAbs increased (lower afﬁnity)
when assayed with rED3 containing substitutions of N390D/S (Table 2).
The effects of the amino acid variation on the DENV complex-
reactive antigenic site were also evaluated. Three DENV complex-
reactive mAbs (20-783-74014, GTX29202 and MD-05-0104) were
used to determine if the substitutions among the viruses altered the
afﬁnities of the mAbs for their epitopes. In comparison to the DENV-
2 type-speciﬁc mAbs, the afﬁnities of most of the DENV complex-
reactive mAbs for the six rED3s were not signiﬁcantly affected by
the amino acid differences among the rED3s (Table 2). The afﬁnities                  300       310       320       330       3
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Fig. 2. Alignment of the ED3 amino acid sequences (E residues 294–400) of six represen
SML6420 (American), PR159 (American), DaKaR578 (sylvatic), and DaKHD10674 (sylvatic)of mAbs GTX29202 and MD-05-0104 did not differ signiﬁcantly for
any of the rED3s. The mAb 20-783-74014 was the only DENV
complex-reactive mAb whose afﬁnities for the rED3s differed signiﬁ-
cantly; the largest difference occurred between NGC (KD=0.46±
0.04 nM) and SML6420 (V308I and N390D, KD=0.22±0.03nM), a
two-fold difference; as determined by one-way ANOVA (P b0.05),
this did not occur with V308I alone (KD=0.5±0.05nM).
The effects of antibody afﬁnity on neutralization
Since neutralization has been correlated with the afﬁnity of an
antibody for its epitope (Gromowski and Barrett, 2007; Gromowski
et al., 2008), neutralization assays were used to determine if the dif-
ferences in physical binding translated into biological differences in
neutralization. Differences in neutralization between the genotype
representatives were evaluated using plaque reduction neutralization
tests (PRNT50) (Table 3). Analysis of mAb 3H5 neutralization showed
that the PRNT50 concentrations for NGC, DakHD10674, H8-2027 and
SML6420 viruses did not differ signiﬁcantly. An example of a neutral-
ization curve is shown in Fig. 3A. Even though the physical binding
(as determined by KD) of the mAb 3H5 for rED3 was different
among the viruses tested, the biological affects as shown by PRNT50
concentrations were not statistically different. The Hill slopes for the
PRNT50 with mAb 3H5 also did not differ signiﬁcantly either, with
1.1±0.1 for NGC, 2.0±0.3 for DAKHD10674, 1.3±0.2 for SML6420,
and 1.1±0.2 for H8-2027. The similar shapes of the neutralization
dose–response curves for these four viruses indicate that the efﬁcacy
of mAb 3H5 to neutralize these viruses is equivalent.
The neutralization data for the DENV complex-reactive mAbs
yielded similar results to the DENV-2 type-speciﬁc mAbs (Table 3).
All three DENV complex reactive mAbs had similar PRNT50 concentra-
tions and Hill slopes. The neutralization curve for GTX29202 is shown
in Fig. 3B as an example. Even though the PRNT50 concentrations are
not signiﬁcantly different between the four viruses, the Hill-slopes for
these viruses did differ signiﬁcantly. The Hill-slopes for these viruses
were 1.0±0.6, 1.7±0.3, 1.0±0.2, and 0.7±0.1 for mAb GTX29202
with NGC, DaKHD10674, and SML6420, respectively. The signiﬁcant
difference was between the Hill-slopes of strains DaKHD10674
and SML6420. As seen in Fig. 3B, the neutralization curve for
DaKHD10674 is steeper than the other two viruses, whereas both
NGC and SML6420 have shallow neutralization curves indicating dif-
ferences in mAb efﬁcacy between DaKHD10674 and NGC and
SML6420. The PRNT50 concentrations for each virus demonstrated
an approximate 20-fold difference between the KD of the mAb for
rED3 and the PRNT50 concentration, which was similar to that
reported previously for DENV-2 strain NGC (Gromowski et al., 2008).
Conservation of the DENV-2 type-speciﬁc and DENV complex-reactive
critical residues in rED3
Since our panel of mAbs was able to bind and neutralize a diverse
group of DENV-2 strains, we investigated whether or not the DENV-2
type-speciﬁc and DENV complex-reactive critical residues identiﬁed
using strain NGC were also important for mAb binding to other DENV-
2 viruses. We (Gromowski and Barrett, 2007; Gromowski et al., 2008)
and others (Sukupolvi-Petty et al., 2007) have shown that a limited sub-
set of residues are critically important for mAb binding to rED3. The40       350       360       370       380       390 
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tative DENV-2 strains from four genotypes: NGC (Asian II), H8-2027 (cosmopolitan),
.
Table 2
mAb Dissociation constants (KD) for representative DENV-2 rED3s.
DENV-2
Genotype
DENV-2
Strains
Type-speciﬁc mAbs Complex-reactive mAbs
3H5 (nM) ICL2 (nM) 20-783-74014 (nM) GTX29202 (nM) MD-05-0104 (nM)
Asian II New Guinea C 1.2±0.1 1.3±0.1 0.46±0.04 0.25±0.02 0.46±0.03
Cosmopolitan H8-2027 3.2±0.3a 2.1±0.2a 0.30±0.06a 0.23±0.02 0.52±0.5
Sylvatic DaKHD10674 0.5±0.04b 0.67±0.1a,b 0.30±0.05 0.20±0.02 0.32±0.03
Sylvatic DaKaR578 1.2±0.1b 1.0±0.1b 0.28±0.04 0.22±0.02 0.34±0.03
American SML6420 4.9±0.5a,b,c,d,f 2.1±0.3a,c,d 0.22±0.03a 0.17±0.02 0.21±0.02
American PR159 2.6±0.3c 2.4±0.3a,c,d 0.35±0.07 0.20±0.03 0.52±0.06
a Signiﬁcantly different from NGC.
b Different from H8-2027.
c Different from DaKHD10674.
d Different from DAKAR578.
e Different from SML6420.
f Different from PR159.
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K305A/E (Gromowski and Barrett, 2007; Sukupolvi-Petty et al., 2007),
K307N/Q/I/E (Sukupolvi-Petty et al., 2007), K310E/A (Gromowski et
al., 2008; Sukupolvi-Petty et al., 2007), E383G (Gromowski and
Barrett, 2007; Sukupolvi-Petty et al., 2007), P384A/N (Gromowski and
Barrett, 2007; Sukupolvi-Petty et al., 2007). We chose to focus on the
critical residues that are shared among mAbs studied thus far; K305A
and P384A for the DENV-2 type-speciﬁc antigenic site and K310A for
the DENV complex-reactive mAbs. We engineered each DENV rED3
used in this study with either K305A and P384A substitutions (DENV-
2 type-speciﬁc antigenic site) or K310A substitution (DENV complex-
reactive antigenic site). These proteins were used in ELISAs to deter-
mine if these critical residues are conserved among the four DENV-2
genotypes tested.
For the DENV-2 type-speciﬁc mAbs 3H5 and ICL2, regardless of the
virus strain, residues K305 and P384 were critical for antibody binding
(Table 4). The afﬁnity of thesemAbs for rED3 containing these substitu-
tions was greatly reduced; the rED3s from NGC, DakHD10674, PR159,
and SML6420 that contained K305A and P384A all resulted in afﬁnity
changes of greater than 50-fold, and formAb ICL2many of these substi-
tutions resulted in essentially complete loss of binding to rED3. As
expected, both of the DENV-2 type-speciﬁc mAbs were unaffected by
the DENV complex-reactive epitope substitution of K310A in any of
the different virus strains.
The binding of the DENV complex-reactive mAbs to the DENV-2
rED3mutants followed a similar pattern with binding of mAbs greatly
reduced for all of the rED3s containing the K310A substitution
(Table 4). All three mAbs bound well to the wild-type rED3 proteins,
and as expected binding was unaffected by the DENV-2 type-speciﬁc
substitutions of K305A and P384A for all of the virus backgrounds.
Only the DENV-2 NGC rED3 with the K305A and P384A substitutions
showed a small change in afﬁnity of 3.5- (mAb 20-783-74014) to 5.2-
(mAb MD-05-0104) fold.
Discussion
The objective of this study was to assess the impact of the natural-
ly occurring amino acid diversity in ED3 among DENV-2 genotypes on
the physical binding of antibodies to ED3, and their subsequentTable 3
Plaque reduction neutralization test (50%) values for representative DENV-2s.
DENV-2
genotype
DENV-2
strains
Type-speciﬁc mAbs
3H5 (nM) ICL2 (nM)
Asian II New Guinea C 1.1±0.1 4.2±0.6
cosmopolitan H8-2027 2.7±0.6 3.3±0.8
sylvatic DaKHD10674 1.7±0.1 3.7±0.8
American SML6420 1.5±0.2 3.5±0.5biological activity of neutralization. In addition, another goal of
this study was to determine if the DENV-2 type-speciﬁc and DEN
complex-reactive antigenic sites were conserved among diverse
DENV-2 genotypes. These questions were investigated using a panel
of ﬁve mAbs (two DENV-2 type-speciﬁc and three DENV complex-
reactive mAbs) that recognize two major overlapping antigenic sites
on ED3, namely DENV-2 type-speciﬁc and DEN virus complex-
reactive. In these assays we utilized representatives from four
DENV-2 genotypes: Asian II (NGC), Cosmopolitan (H8-2027), sylvatic
(DakHD10674 and DakAr578), and American (SML6420 and PR159).
These six viruses represent most of the amino acid variability among
the DENV-2 genotypes in ED3.
The impact of the amino acid variability among the six DENV-2s
on the physical binding was evaluated by ELISA. These assays demon-
strated that each mAb was able to bind rED3 regardless of the differ-
ing residue substitutions among the viruses. However, the amino acid
substitutions among the viruses did alter the afﬁnities of particular
mAbs for rED3. Speciﬁcally, both DENV-2 type-speciﬁc mAbs were
affected by the differing residue combinations more than the three
DEN complex-reactive mAbs. The afﬁnities of mAb 3H5 for almost
all of the rED3s were different, the largest differences in KD were
approximately 10-fold between DaKHD10674 and SML6420; the
ED3 sequences of DaKHD10674 and SML6420 differ by twelve
amino acids (Fig. 2). DaKHD10674 has ﬁve surface exposed residue
changes (D329E, G330D, R345K, T359I, and E360G) compared to the
two surface exposed residue changes in SML6420 (V308I and
N390D). Residues that are surface exposed may be more important
for ligand interactions because they can directly contribute to the
binding interaction and their side-chains are not buried inside the
protein. Interestingly, when mAb 3H5 was used in a neutralization
assay (PRNT50), there was no signiﬁcant difference in the neutraliza-
tion for any of the four viruses tested.
Similar patterns were seen with the other DENV-2 type-speciﬁc
mAb and with DENV complex-reactive mAb 20-783-74014. Taken to-
gether, these data show that mAb afﬁnity for rED3 can differ 10-fold
without having a direct affect on the biological activity of neutraliza-
tion. Clearly, neutralization is determined by factors other than anti-
body afﬁnity. A similar phenomenon has been reported for DENV-1
strains 16007 and West Pac-74; where the afﬁnity of mAb for ED3Complex-reactive mAbs
GTX29202 (nM) 20-783-74014 (nM) MD-05-0104 (nM)
3.3±0.6 7.5±1.8 10.5±1.7
8.0±2.0 6.8±1.1 6.9±1.4
4.3±0.5 9.1±1.3 11.7±1.6
3.6±1.2 3.1±1.2 9.1±2.6
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Fig. 3. Neutralization of different DENV-2 genotype viruses by DENV-2 type speciﬁc
and DENV complex reactive mAbs. Panel A: A representative neutralization curve
of mAb 3H5 with NGC (● black), DakHD10674 (○ green), SML6420 (▲ blue), and
H8-2027 (▼ red). Panel B: A representative neutralization curve with complex-
reactive mAb GTX29202 with NGC (● black), DakHD10674 (○ green), SML6420
(▲ blue), H8-2027 (▼ red).
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viruses were strikingly different (Shrestha et al., 2010).
Our results complement a recent study by Sukupolvi-Petty et al.
(2010), where the effects of DENV-2 amino acid diversity in the ETable 4
Relative dissociation constants of mutant rED3 as compared to the wild type rED3.
rED3 Type-speciﬁc mAbs
3H5 ICL2
NGC 1 1
NGC K305A+P384A ≥50.0 ≥50.0
NGC K310A 4.4 1.9
DaKHD10674 1 1
DaKHD10674 K305A+P384A ≥50.0 46.9
DaKHD10674 K310A 1.4 1.9
PR159 1 1
PR159 K305A+P384A ≥50.0 ≥50.0
PR159 K310A 1.6 1.7
SML6420 1 1
SML6420 K305A+P384A ≥50.0 ≥50.0
SML6420 K310A 3.2 2.8protein on antibody-mediated neutralization with mAbs generated
in alpha/beta interferon receptor-deﬁcient C57BL/6 mice were ana-
lyzed. As with our study, Sukupolvi-Petty et al.(2010) also showed
that all of the ED3 mAbs tested could effectively neutralize DENV-2s
from diverse genotypes. The major impact of genotypic variation
was seen with the sylvatic virus PM33974 (three amino acid substitu-
tions, G330D, R345K, V365I), where the substitution G330D reduced
binding of two mAbs to rED3, and increased the quantity of these
mAbs needed to neutralize the virus (Sukupolvi-Petty et al., 2010).
In comparison, none of the mAbs used in this study were directly
affected by the G330D substitution. Two of the rED3s used in
this study contained the G330D substitution (DaKHD10674 and
DakAr578), and the substitutions in these rED3s either increased
the afﬁnity (DakHD10674) or had no effect (DakAr578) as compared
to the binding of mAbs to rED3 of NGC. Both DENV-2 type-speciﬁc
and DEN complex-reactive mAbs neutralized DakHD10674 at the
same concentration for all viruses studied. One major difference
between our study and that of Sukupolvi-Petty et al. is the source of
the mAbs used. The mAbs used in this study were generated in a
BALB/c background immunized with whole virus; whereas the
mAbs used in Sukupolvi-Petty et al.(2010) were generated in a
C57BL/6 background following immunization with whole virus and
then boosted with rED3. Even though many of the critical residues
identiﬁed by Sukupolvi-Petty et al. are shared by the mAbs used in
this study, some of their mAbs were sensitive to residue changes in
other regions of ED3 not shared by our mAbs, indicating that anti-
bodies produced in the C57BL/6 background may not be identical to
those produced in BALB/c background, which may be due to different
MHC haplotypes of the mice. In contrast to recent studies on DENV-3
(Brien et al., 2010; Wahala et al., 2010), DENV-2 type-speciﬁc and
DEN complex-reactive mAbs targeting ED3 are able to effectively
bind and neutralize diverse DENV-2 strains from most of the geno-
types; whereas mAbs that recognize DENV-3 ED3 cannot bind and
neutralize viruses from all genotypes. DENV-3 has a greater number
of variable residues in ED3 compared to DENV-2 and more of these
variable residues are critical for mAb binding (Brien et al., 2010;
Wahala et al., 2010). DENV-3 also has more critical residues for the
DENV-3 type-speciﬁc and DEN complex-reactive antigenic sites than
DENV-2 (Brien et al., 2010; Matsui et al., 2009, 2010; Wahala et al.,
2010). Thus, amino acid differences in DENV-3 ED3 are more likely
to disrupt antibody binding and neutralization than amino acid vari-
ation in DENV-2.
It was important to determine if the DENV-2 type-speciﬁc and
DEN complex-reactive critical residues were shared across all of the
DENVs tested. This was investigated by expressing rED3s with alanine
substitutions at the positions of the previously identiﬁed critical
residues K305A and P384A (DENV-2 type-speciﬁc) or K310A (DEN
complex-reactive)(Gromowski and Barrett, 2007; Gromowski et al.,
2008; Sukupolvi-Petty et al., 2007) in the background of NGC,Complex-reactive mAbs
20-783-74014 GTX29202 MD-05-0104
1 1 1
3.5 4.8 5.2
39 ≥50.0 ≥50.0
1 1 1
1 1 0.8
9.7 ≥50.0 ≥50.0
1 1 1
1 1.4 1.3
≥50.0 ≥50.0 ≥50.0
1 1 1
1.7 1.3 1.5
≥50.0 ≥50.0 ≥50.0
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3H5 and ICL2 were both affected by the substitutions K305A and
P384A regardless of the virus background. This indicates that the
DENV-2 type-speciﬁc antigenic site has the same critical residues
for different genotypes. The complex-reactive mAbs were all sensitive
to the substitution at K310A, regardless of the virus genotype indicat-
ing that the critical residue for the DEN complex reactive antigenic
site is conserved between DENV-2 genotypes. Overall, these data
demonstrate that the most of the DENV-2 type-speciﬁc and DEN
complex-reactive mAbs bind the same region of ED3 regardless of
the DENV-2 genotype and that substitutions affecting one antigenic
site are speciﬁc and do not broadly affect the other antigenic site on
the surface of ED3. This was expected since in our previous study
(Gromowski et al., 2010) we demonstrated that substitutions of the
critical residues K305A, P384A, or K310A do not dramatically alter
the structure of DENV-2 NGC ED3.
The results of this study have shown that the amino acid variation
in ED3 can affect the binding of the DENV-2 type-speciﬁc and one of
the DEN complex-reactive mAbs for ED3, but that these changes in
mAb afﬁnity for ED3 do not affect the concentration at which neu-
tralization takes place. Furthermore, we have shown in this study
that the critical residues that make up the DENV-2 type-speciﬁc
and DEN complex-reactive antigenic sites are essentially conserved
among four of the DENV-2 genotypes and that substitution of these
residues ablates antibody binding. Taken together the results indi-
cate that the amino acid variation among in ED3 among the geno-
types does not greatly affect antibodies that bind these antigenic
sites and that ED3 targeting antibodies will be protective against
diverse DENV-2 strains. This is important for a potential DENV-2
vaccine since it will be based upon a single representative DENV-2
strain.Materials and methods
Cells and viruses
Vero cells (African green monkey kidney) were maintained at
37 °C in a 5% CO2 incubator in minimum essential media (Gibco) sup-
plemented with 10% bovine growth serum, 1% L-glutamine, 1% non-
essential amino acids, and 1% penicillin/streptomycin. C6/36 mos-
quito cells were maintained at 28 °C in minimum essential media
supplemented with 10% fetal bovine serum, 5% tryptose phosphate
buffer, 1% L-glutamine, 1% non-essential amino acids, and 1% penicillin/
streptomycin. The DENV-2 strains used in this study, New Guinea C
(NGC) (Asian II), H8-2027 (cosmopolitan), DakHD10674 (sylvatic), and
SML6420 (American) were ampliﬁed in C6/36 cells and then titrated
by plaque assay in Vero cells.Monoclonal antibodies (mAbs)
Five commercially available mAbs were used in this study: 3H5
(Millipore, immunogen DENV-2 New Guinea C (Gentry et al., 1982),
ICL2 (Santa Cruz Biotechnologies, DENV-2 immunogen), 20-783-
74014 (Gen Way Bio, immunogens: mixture of DENV-1, -2, -3, and -4),
GTX29202 (GeneTex, immunogens: mixture of DENV-1, -2, -3, and -4),
and MD-05-0104 (Ray Biotech, immunogens: DENV-1 Hawaii,
DENV-2 New Guinea C, DENV-3 H87, and DENV-4 H-241). All ﬁve
antibodies were afﬁnity puriﬁed. MAbs 3H5, and ICL2 are mouse
IgG1 DENV-2 type-speciﬁc while the mAbs 20-783-74014, GTX29202,
and MD-05-0104 are mouse IgG2a DENV sub-complex-reactive.
The mAb 3H5 (Millipore) was used as a control in all enzyme
linked immunoabsorpbent assays (ELISAs), and 50% plaque reduction
neutralization tests (PRNT50) to ensure consistency among the
replicates and assays.Site-directed mutagenesis
Site-directed mutagenesis of the rED3 MBP fusion construct con-
tained in the pMAL-C2x vector was performed using the QuikChange
XL 2 kit (Stratagene) according to the manufacturer's directions. The
engineered substitutions were conﬁrmed by sequencing.
Expression and puriﬁcation of recombinant DENV-2 ED3
The DENV-2 rED3s were cloned and expressed as described previ-
ously (Gromowski and Barrett, 2007). Brieﬂy the bacterial lysates
containing the expressed proteins were applied to 2 ml centrifuge
columns (Pierce) packed with amylose resin (New England Biolabs),
and eluted using column buffer (10 mM Tris pH 7.2, 100 mM NaCl,
50 mM EDTA) containing 10 mM maltose. The concentration of the
puriﬁed protein was quantiﬁed using the BCA kit (Pierce) as directed
by the manufacturer.
Afﬁnity measurements by indirect ELISA with rED3
The ELISAs with the rED3 were preformed as described previously
(Gromowski and Barrett, 2007; Gromowski et al., 2008). In the ELISAs
the type-speciﬁc mAbs were diluted in blocking buffer to 80 nM
(3H5, and ICL2). ICL2 was diluted to 160 nM for wells containing
rED3s for DENV-2 strains H8-2027, SML6420, and PR159, and 80 nM
for the rED3 of DENV-2 strains NGC, DakHD10674, and DakAr578.
The complex-reactive mAbs 20-783-74014, GTX29202, and MD-05-
0104 were diluted in blocking buffer to 10 nM (MD-05-0104 was di-
luted to 20 nM for the wells containing the rED3s H8-2027, SML6420,
and PR159, and 10 nM for NGC, DakHD10674, and DakAr578). The
mAbs were serially diluted two-fold and were incubated overnight
at room temperature. The following day the mAbs were removed,
the plates were washed, and incubated with goat anti-mouse IgG
conjugated with horseradish peroxidase (IgG-HRP) diluted 1/1000.
Antibody bindingwas visualized using 3, 3′, 5, 5′-tetramethylbenzidene
substrate (Sigma) and read at 655 nm on a UV-plate reader (BioRad).
The KD values for eachMAb calculated using non-linear regression anal-
ysis (single site binding saturation) SigmaPlot as described previously
(Gromowski and Barrett, 2007). Each mAb was tested in duplicate per
assay and results are an average of 5 experiments.
Plaque assays and Plaque reduction neutralization tests (PRNT50)
were performed as described previously (Gromowski and Barrett, 2007).
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